Adaptimmune Therapeutics plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher James Hill
- Full Time Employees
- 506
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Innovation Centre Abingdon OXF United Kingdom OX14 4RX
- IPO Date
- May 6, 2015
- CIK
- 0001621227
- Website
- adaptimmune.com
- Similar Companies
- Business
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on developing engineered T-cell receptor (TCR) therapies, known as SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells, to target solid tumors in cancer patients. The company engineers patients' own T-cells to express affinity-enhanced TCRs that recognize and attack cancer cells expressing specific antigens such as MAGE-A4, NY-ESO-1, PRAME, and CD70; its lead approved product is TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy approved by the FDA for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy; its pipeline includes lete-cel (letetresgene autoleucel) for synovial sarcoma and myxoid/round cell liposarcoma (with a rolling Biologics License Application submission planned for late 2025 and potential approval in 2026), uza-cel (ADP-5701) in Phase 1 for head and neck cancer, ADP-A2M4CD8 in Phase 2 trials for platinum-resistant ovarian cancer and other solid tumors, and preclinical programs targeting PRAME (ADP-600) and CD70 (ADP-520). Adaptimmune operates primarily in the United States and United Kingdom, with manufacturing capabilities in Philadelphia, Pennsylvania, and additional sites in Cambridge, Massachusetts; it was founded in 2008 as a spin-out from MediGene AG's UK research subsidiary and is headquartered at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. In July 2025, the company entered a definitive agreement to sell its sarcoma franchise assets—including TECELRA, lete-cel, afami-cel, and uza-cel—to US WorldMeds for $55 million upfront plus up to $30 million in milestones, retaining rights to preclinical assets like PRAME, CD70, and allogeneic programs while restructuring operations, repaying debt, and reducing headcount by 29% to achieve $300 million in cost savings over four years; this followed Q2 2025 TECELRA net sales of $11.1 million (over 150% growth from Q1), activation of 20 Authorized Treatment Centers, and plans for operating profitability by 2027, with the company announcing voluntary delisting from Nasdaq in October 2025 to cut compliance costs. Strategic collaborations include partnerships with Galapagos for decentralized manufacturing of uza-cel, Noile-Immune Biotech, Alpine Immune Sciences, Universal Cells, Genentech, F. Hoffman-La Roche, and MD Anderson Cancer Center for co-development and clinical evaluation of TCR T-cell therapies.
Adaptimmune Announces Changes to Board and Executive Leadership Team
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Adaptimmune Announces Delisting from Nasdaq
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Reports Q3 2024 Financial and Business Updates
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024